Kaijun Li
Direttore Tecnico/Scientifico/R&S presso China Nuokang Bio-Pharmaceutical, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Dan Zhang | M | - |
ClinChoice Medical (TIANJIN) Co., Ltd.
ClinChoice Medical (TIANJIN) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services ClinChoice Medical (TIANJIN) Co., Ltd. operates as a contract research organization. It offers consulting, project management, clinical operations, data reporting and laboratory services. The firm also provides good clinical practice compliant clinical research services for multinational clients. The company was founded by Young Wang, Kaijun Li, Dan Zhang and Joanne Jiang Chen in October 2006 and is headquartered in Beijing, the Republic of China. | 18 anni |
Bai Zhong Xue | M | 59 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 27 anni |
Xiao Ying Gao | M | 74 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 13 anni |
Sean Shao | M | 67 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 16 anni |
Qiang Liu | M | 58 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 18 anni |
Shizheng Duan | M | 56 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 20 anni |
Huining Cao | M | 58 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 14 anni |
Joanne Jiang | M | - |
ClinChoice Medical (TIANJIN) Co., Ltd.
ClinChoice Medical (TIANJIN) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services ClinChoice Medical (TIANJIN) Co., Ltd. operates as a contract research organization. It offers consulting, project management, clinical operations, data reporting and laboratory services. The firm also provides good clinical practice compliant clinical research services for multinational clients. The company was founded by Young Wang, Kaijun Li, Dan Zhang and Joanne Jiang Chen in October 2006 and is headquartered in Beijing, the Republic of China. | 18 anni |
Felix Chungfai Wong | M | - |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 12 anni |
Hongying Wang | F | 51 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 26 anni |
Yong Xu | M | 59 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 18 anni |
Yan Xue | F | 47 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 22 anni |
Jiuxiang Li | M | 53 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 20 anni |
Tong Le | M | - |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 12 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
William Keller | M | 75 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China.
HBM BioMed China Partners Ltd
HBM BioMed China Partners Ltd Investment ManagersFinance HBM BioMed China Partners Ltd. is a venture capital fund focused on biomedical investments in companies based in China. | 4 anni |
Li Xin Niu | F | 52 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 6 anni |
Jeffrey David McGhie | M | 54 |
Indiana University
| 5 anni |
Jason Charney | M | - |
Indiana University
| 5 anni |
Kamlesh Rath | M | - |
Indiana University
| 6 anni |
Michael J. Riley | M | - |
Indiana University
| 5 anni |
Michael Riley | M | - |
Indiana University
| 6 anni |
Ming De Yu | M | 78 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 5 anni |
Colin Hudson | M | - |
Indiana University
| 4 anni |
Andrew Waisburd | M | - |
Indiana University
| 5 anni |
Pantro Pander Silitonga | M | 48 |
Indiana University
| 4 anni |
Patrick Heim | M | - |
Indiana University
| 1 anni |
Jared R. Daniels | M | - |
Indiana University
| 4 anni |
Scott Overholser | M | - |
Indiana University
| 3 anni |
King Hang Li | M | 80 |
Indiana University
| 34 anni |
Jong-Woo Kim | M | 56 |
Indiana University
| 3 anni |
Aaron Christian Scully | M | - |
Indiana University
| 4 anni |
Todd Alan Poellein | M | - |
Indiana University
| 4 anni |
Stuart R. Robertson | M | - |
Indiana University
| 2 anni |
Peter Song | M | - |
Indiana University
| 3 anni |
Brandon Minassian Pellegrino | M | - |
Indiana University
| 4 anni |
Chad Fitzgerald | M | - |
Indiana University
| - |
Dair Adilbekovich Kusherov | M | 47 |
Indiana University
| 4 anni |
Chad Mooney | M | - |
Indiana University
| 4 anni |
Michael B. Edwards | M | 55 |
Indiana University
| 4 anni |
Jason Paul Schretter | M | 48 |
Indiana University
| 4 anni |
Lay Ban Teo | M | 50 |
Indiana University
| 4 anni |
Amanda Nolen | F | - |
Indiana University
| 4 anni |
Kowinski Katie | F | - |
Indiana University
| 4 anni |
Ryan Williamson | M | - |
Indiana University
| 4 anni |
Jon Gladieux | M | - |
Indiana University
| 4 anni |
Khaled Awad Taha | M | - |
Indiana University
| 4 anni |
Terry Stapp | M | - |
Indiana University
| 4 anni |
Dewi Irianty Wijaya | F | 46 |
Indiana University
| 4 anni |
Alexander Tio | M | 44 |
Indiana University
| 4 anni |
Daniel Sailer | M | 44 |
Indiana University
| 5 anni |
Andrea Unzicker | F | - |
Indiana University
| 3 anni |
Nasser Mohammad Saleh Obaid | M | 56 |
Indiana University
| 4 anni |
Ronald D. Brown | M | 59 |
Indiana University
| 1 anni |
Christopher Brewster | M | - |
Indiana University
| 4 anni |
Zach Fleming | M | 49 |
Indiana University
| 4 anni |
Ryan Kitchell | M | 50 |
Indiana University
| 4 anni |
Nir Kaissar | M | - |
Indiana University
| 4 anni |
James Beckett | M | - |
Indiana University
| 3 anni |
Jason Phipps | M | 52 |
Indiana University
| 4 anni |
Richard T. Pines | M | - |
Indiana University
| 4 anni |
Michael Gapen | M | - |
Indiana University
| 3 anni |
Thomas Lipkin | M | - |
Indiana University
| 4 anni |
Gary N. Hoipkemier | M | - |
Indiana University
| 2 anni |
Elliot Pessis | M | - |
Indiana University
| 5 anni |
Bryan H. Babb | M | - |
Indiana University
| 3 anni |
Stephan Allan Colglazier | M | 50 |
Indiana University
| 4 anni |
Greg Maurer | M | - |
Indiana University
| 4 anni |
Melina M. Kennedy | F | 54 |
Indiana University
| 3 anni |
John Wendell Rosebrough | M | - |
Indiana University
| 4 anni |
Joshua Leavitt | M | - |
Indiana University
| 4 anni |
Harpi Madan | M | - |
Indiana University
| 2 anni |
Janice Catherine Wilken | F | 51 |
Indiana University
| 3 anni |
Linda G. Hunter | F | - |
Indiana University
| 4 anni |
Daniel Herz | M | 47 |
Indiana University
| 3 anni |
Jeff Bailey | M | - |
Indiana University
| 4 anni |
John Ptak | M | - |
Indiana University
| 4 anni |
Casey A. Basil | M | - |
Indiana University
| 4 anni |
John M. Carsello | M | - |
Indiana University
| 4 anni |
Jeff Shelton | M | - |
Indiana University
| 2 anni |
Garrick Venteicher | M | - |
Indiana University
| 2 anni |
Kyle Hupfer | M | - |
Indiana University
| 4 anni |
Troy Allen Davig | M | - |
Indiana University
| 5 anni |
Leny Suparman | F | 50 |
Indiana University
| 4 anni |
Adam Lippman | M | - |
Indiana University
| 4 anni |
Thomas A. Edler | M | 81 |
Indiana University
| 4 anni |
Seth E. Tobin | M | - |
Indiana University
| 3 anni |
Laura K. Albrecht | F | - |
Indiana University
| 4 anni |
Michael Richley | M | - |
Indiana University
| 4 anni |
Michael Holt | M | - |
Indiana University
| 4 anni |
Brad A. Glotzbach | M | - |
Indiana University
| 4 anni |
Eric Ottinger | M | 53 |
Indiana University
| 2 anni |
Gang Yi | M | 66 |
Indiana University
| 8 anni |
Dean Hilderhoff | M | - |
Indiana University
| 1 anni |
Matt Kenaston | M | - |
Indiana University
| 4 anni |
JC Chetnani | M | 51 |
Indiana University
| 2 anni |
Pei Dong Wu | M | 59 |
Indiana University
| 3 anni |
Sarah Early | F | - |
Indiana University
| 4 anni |
Erin Elizabeth Carney | F | - |
Indiana University
| 4 anni |
Tom Eidelman | M | 45 |
Indiana University
| 4 anni |
Stevie Clements | F | - |
Indiana University
| 5 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 83 | 83.00% |
Cina | 17 | 17.00% |
Hong Kong | 1 | 1.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Kaijun Li
- Contatti personali